BIONUMERIK
BioNumerik Pharmaceuticals, Inc.
Application Filed: 2005-03-24
Trademark Application Details
CANCELLED - SECTION 8
| Research |
OneLook
Acronym Finder
|
| Serial Number | 78593946 |
| Registration Number | 3703574 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Cancellation Code | 2 |
| Attorney Name | Laura A. Genovese |
| Attorney Docket Number | 066131.0059 |
| Law Office Assigned | M30 |
| Employee Name | OKEKE, BENJAMIN U |
Timeline
| 1996-05-31 | Date of First Use |
| 2005-03-24 | Application Filed |
| 2006-07-25 | Published for Opposition |
| 2009-09-21 | Location: PUBLICATION AND ISSUE SECTION |
| 2009-10-27 | Trademark Registered |
| 2016-06-03 | Cancelled |
| 2016-06-03 | Status: Dead/Cancelled |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  BioNumerik Pharmaceuticals, Inc. |
| Address | 8122 Datapoint Drive, Suite 1250 San Antonio TX 78229 |
| Legal Entity Type | Corporation |
| Legal Entity State | TX |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical products for the following diseases and medical conditions; cancer; sickle cell anemia; the toxicity of side-effects of chemotherapeutic treatment; neurotoxicity; adult respiratory distress syndrome; acute renal failure treatment; septic shock or shock/ischemia; ethanol-induced physiological symptoms ("Hang-over"); ethylene glycol poisoning; radiation exposure; osteoporosis; cardiomyopathy; diabetic neuropathy; diabetic opthalmopathy; diabetic angiopathy; diabetic nephropathy; hypertension; atherosclerosis and peripheral vascular disease; ischemia; gastrointestinal distress; patients exposed to toxic chemicals; heavy metal poisoning or exposure; complications arising from AIDS; alcoholism and complications arising therefrom; acetaminophen overdosage; the renal calculi (kidney stones); inhibiting angiogenesis; Wilson's disease; Treatment for reducing toxicity associated with diabetes treatments; inflammatory bowel disorder; complication arising from tobacco smoke exposure; venomous snakebite; patients undergoing kidney dialysis or peritoneal dialysis; chemotherapy/drug extravasation injury; lymphedema; chemotherapy- or drug-induced toxicity; platinum or alkylating agent overdose; hyperbaric toxicity; chemotherapy- or radiation-induced mucositis |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2005-03-29 | 1 NWAP I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2005-10-19 | 2 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2005-10-19 | 3 CNRT R:Renewal |
| NON-FINAL ACTION MAILED | 2005-10-20 | 4 CNRT F:First Action |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2006-04-12 | 5 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2006-04-12 | 6 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2006-04-21 | 7 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2006-05-12 | 8 CNSA P: |
| ASSIGNED TO LIE | 2006-05-26 | 9 ALIE A:Allowance for Publication |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2006-06-02 | 10 PREV O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2006-07-05 | 11 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 2006-07-25 | 12 PUBO A:Allowance for Publication |
| NOA MAILED - SOU REQUIRED FROM APPLICANT | 2006-10-17 | 13 NOAM O:Outgoing Correspondence |
| TEAS EXTENSION RECEIVED | 2007-04-10 | 14 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2007-04-10 | 15 EXT1 S: |
| EXTENSION 1 GRANTED | 2007-04-10 | 16 EX1G S: |
| TEAS EXTENSION RECEIVED | 2007-09-14 | 17 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2007-09-14 | 18 EXT2 S: |
| EXTENSION 2 GRANTED | 2007-09-14 | 19 EX2G S: |
| TEAS EXTENSION RECEIVED | 2007-11-08 | 20 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2007-11-08 | 21 EXT3 S: |
| EXTENSION 3 GRANTED | 2007-11-08 | 22 EX3G S: |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2008-01-09 | 23 TCCA I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2008-02-05 | 24 DOCK D:Assigned to Examiner |
| TEAS EXTENSION RECEIVED | 2008-09-23 | 25 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2008-09-23 | 26 EXT4 S: |
| EXTENSION 4 GRANTED | 2008-09-23 | 27 EX4G S: |
| TEAS EXTENSION RECEIVED | 2009-01-09 | 28 EEXT I:Incoming Correspondence |
| EXTENSION 5 FILED | 2009-01-09 | 29 EXT5 S: |
| EXTENSION 5 GRANTED | 2009-01-09 | 30 EX5G S: |
| TEAS STATEMENT OF USE RECEIVED | 2009-06-16 | 31 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2009-07-10 | 32 AITU A:Allowance for Publication |
| USE AMENDMENT FILED | 2009-06-16 | 33 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2009-07-10 | 34 SUPC I:Incoming Correspondence |
| SU - NON-FINAL ACTION - WRITTEN | 2009-08-06 | 35 CNRT W: |
| NON-FINAL ACTION E-MAILED | 2009-08-06 | 36 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2009-08-06 | 37 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2009-08-24 | 38 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2009-08-24 | 39 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2009-08-24 | 40 TEME I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2009-09-11 | 41 CNPR P: |
| ASSIGNED TO LIE | 2009-09-21 | 42 ALIE A:Allowance for Publication |
| LAW OFFICE REGISTRATION REVIEW COMPLETED | 2009-09-21 | 43 REGV O:Outgoing Correspondence |
| REGISTERED-PRINCIPAL REGISTER | 2009-10-27 | 44 R.PR A:Allowance for Publication |
| CANCELLED SEC. 8 (6-YR) | 2016-06-03 | 45 C8.. O:Outgoing Correspondence |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 